Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data.

Cancers (Basel) · 2025 · PMC12153560 · PMID 40507314

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the trial’s results indicated that patients treated with ipilimumab plus dacarbazine had a significantly longer survival than those treated with dacarbazine plus placebo (HR = −0.33, 95% CI −0.53 to −0.14), the survival benefit did not reach statistical significance in a subgroup analysis of patients aged ≥ 65 years (HR = −0.09, 95% CI −0.44 to −0.25).

also in 57,694 other papers

not clearly significantno p-value reported

In the CheckMate 238 trial, the efficacy of nivolumab was statistically significant for patients < 65 years (HR = 0.72, 95% CI 0.58–0.89), while in the older group of patients (25.8% of all included patients with age ≥ 65 years), the efficacy was not clearly significant (HR = 0.72, 95% CI 0.51–1.00).

also in 15 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.